{"entity":{"type":"insider","cik":"0001654586","url":"/insider/0001654586","json_url":"/insider/0001654586.json","name":"Canaan Partners IX LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":29,"n_filings":15,"first":"2016-05-23","last":"2016-12-01","span_basis":"filed_date"},"name_variants":[{"name":"Canaan Partners IX LLC","source":"filing","n_filings":15,"first_seen":"2016-05-23","last_seen":"2016-12-01"}],"transactions":[{"id":2501847,"accession":"0000899243-16-034627","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-034627","line_url":"/filing/0000899243-16-034627#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22086.0,"shares_display":"22,086","price_per_share":11.1839,"price_display":"11.18","price_state":"stated","total_value":247007.6154,"total_display":"247,007.62","total_whole":"247,008","shares_owned_after":3644381.0,"shares_owned_after_display":"3,644,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-29","filed_date":"2016-12-01","scope":"insider"},{"id":2943040,"accession":"0000899243-16-034442","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-16-034442","line_url":"/filing/0000899243-16-034442#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20840.0,"shares_display":"20,840","price_per_share":11.3312,"price_display":"11.33","price_state":"stated","total_value":236142.208,"total_display":"236,142.21","total_whole":"236,142","shares_owned_after":3666467.0,"shares_owned_after_display":"3,666,467","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-28","filed_date":"2016-11-28","scope":"insider"},{"id":2943034,"accession":"0000899243-16-034442","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-034442","line_url":"/filing/0000899243-16-034442#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6729.0,"shares_display":"6,729","price_per_share":11.7909,"price_display":"11.79","price_state":"stated","total_value":79340.9661,"total_display":"79,340.97","total_whole":"79,341","shares_owned_after":3687307.0,"shares_owned_after_display":"3,687,307","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-25","filed_date":"2016-11-28","scope":"insider"},{"id":2943029,"accession":"0000899243-16-034442","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-034442","line_url":"/filing/0000899243-16-034442#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10890.0,"shares_display":"10,890","price_per_share":11.8385,"price_display":"11.84","price_state":"stated","total_value":128921.265,"total_display":"128,921.26","total_whole":"128,921","shares_owned_after":3694036.0,"shares_owned_after_display":"3,694,036","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-23","filed_date":"2016-11-28","scope":"insider"},{"id":2988880,"accession":"0000899243-16-034194","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-034194","line_url":"/filing/0000899243-16-034194#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":42550.0,"shares_display":"42,550","price_per_share":11.7057,"price_display":"11.71","price_state":"stated","total_value":498077.535,"total_display":"498,077.54","total_whole":"498,078","shares_owned_after":3704926.0,"shares_owned_after_display":"3,704,926","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-22","filed_date":"2016-11-22","scope":"insider"},{"id":2988876,"accession":"0000899243-16-034052","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-16-034052","line_url":"/filing/0000899243-16-034052#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13548.0,"shares_display":"13,548","price_per_share":11.7202,"price_display":"11.72","price_state":"stated","total_value":158785.2696,"total_display":"158,785.27","total_whole":"158,785","shares_owned_after":3747476.0,"shares_owned_after_display":"3,747,476","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-21","filed_date":"2016-11-21","scope":"insider"},{"id":2988873,"accession":"0000899243-16-034052","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-034052","line_url":"/filing/0000899243-16-034052#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12805.0,"shares_display":"12,805","price_per_share":11.6427,"price_display":"11.64","price_state":"stated","total_value":149084.7735,"total_display":"149,084.77","total_whole":"149,085","shares_owned_after":3761024.0,"shares_owned_after_display":"3,761,024","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-18","filed_date":"2016-11-21","scope":"insider"},{"id":2988870,"accession":"0000899243-16-034052","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-034052","line_url":"/filing/0000899243-16-034052#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18971.0,"shares_display":"18,971","price_per_share":11.5027,"price_display":"11.50","price_state":"stated","total_value":218217.7217,"total_display":"218,217.72","total_whole":"218,218","shares_owned_after":3773829.0,"shares_owned_after_display":"3,773,829","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-17","filed_date":"2016-11-21","scope":"insider"},{"id":2863119,"accession":"0000899243-16-033704","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-033704","line_url":"/filing/0000899243-16-033704#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18517.0,"shares_display":"18,517","price_per_share":11.5544,"price_display":"11.55","price_state":"stated","total_value":213952.8248,"total_display":"213,952.82","total_whole":"213,953","shares_owned_after":3792800.0,"shares_owned_after_display":"3,792,800","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-16","filed_date":"2016-11-16","scope":"insider"},{"id":2863114,"accession":"0000899243-16-033704","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-033704","line_url":"/filing/0000899243-16-033704#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33064.0,"shares_display":"33,064","price_per_share":11.477,"price_display":"11.48","price_state":"stated","total_value":379475.528,"total_display":"379,475.53","total_whole":"379,476","shares_owned_after":3811317.0,"shares_owned_after_display":"3,811,317","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-15","filed_date":"2016-11-16","scope":"insider"},{"id":2772732,"accession":"0000899243-16-033335","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-16-033335","line_url":"/filing/0000899243-16-033335#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23744.0,"shares_display":"23,744","price_per_share":11.2052,"price_display":"11.21","price_state":"stated","total_value":266056.2688,"total_display":"266,056.27","total_whole":"266,056","shares_owned_after":3844381.0,"shares_owned_after_display":"3,844,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-14","filed_date":"2016-11-14","scope":"insider"},{"id":2772727,"accession":"0000899243-16-033335","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-033335","line_url":"/filing/0000899243-16-033335#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35391.0,"shares_display":"35,391","price_per_share":11.2023,"price_display":"11.20","price_state":"stated","total_value":396460.5993,"total_display":"396,460.60","total_whole":"396,461","shares_owned_after":3868125.0,"shares_owned_after_display":"3,868,125","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-11","filed_date":"2016-11-14","scope":"insider"},{"id":2772721,"accession":"0000899243-16-033335","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-033335","line_url":"/filing/0000899243-16-033335#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27135.0,"shares_display":"27,135","price_per_share":11.0702,"price_display":"11.07","price_state":"stated","total_value":300389.877,"total_display":"300,389.88","total_whole":"300,390","shares_owned_after":3903516.0,"shares_owned_after_display":"3,903,516","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-10","filed_date":"2016-11-14","scope":"insider"},{"id":3274461,"accession":"0000899243-16-033178","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-033178","line_url":"/filing/0000899243-16-033178#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13730.0,"shares_display":"13,730","price_per_share":11.0341,"price_display":"11.03","price_state":"stated","total_value":151498.193,"total_display":"151,498.19","total_whole":"151,498","shares_owned_after":3930651.0,"shares_owned_after_display":"3,930,651","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-11-09","filed_date":"2016-11-10","scope":"insider"},{"id":2200682,"accession":"0000899243-16-022416","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-16-022416","line_url":"/filing/0000899243-16-022416#line-3","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2700.0,"shares_display":"2,700","price_per_share":10.01,"price_display":"10.01","price_state":"stated","total_value":27027.0,"total_display":"27,027.00","total_whole":"27,027","shares_owned_after":4244381.0,"shares_owned_after_display":"4,244,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-10","filed_date":"2016-06-10","scope":"insider"},{"id":2200678,"accession":"0000899243-16-022416","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-022416","line_url":"/filing/0000899243-16-022416#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22842.0,"shares_display":"22,842","price_per_share":10.06,"price_display":"10.06","price_state":"stated","total_value":229790.52,"total_display":"229,790.52","total_whole":"229,791","shares_owned_after":4247081.0,"shares_owned_after_display":"4,247,081","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-09","filed_date":"2016-06-10","scope":"insider"},{"id":2200677,"accession":"0000899243-16-022416","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-022416","line_url":"/filing/0000899243-16-022416#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22885.0,"shares_display":"22,885","price_per_share":10.08,"price_display":"10.08","price_state":"stated","total_value":230680.8,"total_display":"230,680.80","total_whole":"230,681","shares_owned_after":4269923.0,"shares_owned_after_display":"4,269,923","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-08","filed_date":"2016-06-10","scope":"insider"},{"id":3240296,"accession":"0000899243-16-022180","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-022180","line_url":"/filing/0000899243-16-022180#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9731.0,"shares_display":"9,731","price_per_share":10.03,"price_display":"10.03","price_state":"stated","total_value":97601.93,"total_display":"97,601.93","total_whole":"97,602","shares_owned_after":4292808.0,"shares_owned_after_display":"4,292,808","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-07","filed_date":"2016-06-08","scope":"insider"},{"id":3240290,"accession":"0000899243-16-022180","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-022180","line_url":"/filing/0000899243-16-022180#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":101767.0,"shares_display":"101,767","price_per_share":10.01,"price_display":"10.01","price_state":"stated","total_value":1018687.67,"total_display":"1,018,687.67","total_whole":"1,018,688","shares_owned_after":4302539.0,"shares_owned_after_display":"4,302,539","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-06","filed_date":"2016-06-08","scope":"insider"},{"id":2495362,"accession":"0000899243-16-021783","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-021783","line_url":"/filing/0000899243-16-021783#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18428.0,"shares_display":"18,428","price_per_share":10.83,"price_display":"10.83","price_state":"stated","total_value":199575.24,"total_display":"199,575.24","total_whole":"199,575","shares_owned_after":4404306.0,"shares_owned_after_display":"4,404,306","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-03","filed_date":"2016-06-06","scope":"insider"},{"id":2495356,"accession":"0000899243-16-021783","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-021783","line_url":"/filing/0000899243-16-021783#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan IX L.P.; Canaan Partners IX LLC","owner_display_name":"Canaan IX L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41193.0,"shares_display":"41,193","price_per_share":10.79,"price_display":"10.79","price_state":"stated","total_value":444472.47,"total_display":"444,472.47","total_whole":"444,472","shares_owned_after":4422734.0,"shares_owned_after_display":"4,422,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-02","filed_date":"2016-06-06","scope":"insider"},{"id":2349753,"accession":"0000899243-16-021477","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-021477","line_url":"/filing/0000899243-16-021477#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22463.0,"shares_display":"22,463","price_per_share":10.75,"price_display":"10.75","price_state":"stated","total_value":241477.25,"total_display":"241,477.25","total_whole":"241,477","shares_owned_after":4463927.0,"shares_owned_after_display":"4,463,927","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-06-01","filed_date":"2016-06-02","scope":"insider"},{"id":2305492,"accession":"0000899243-16-021304","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-021304","line_url":"/filing/0000899243-16-021304#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25082.0,"shares_display":"25,082","price_per_share":10.6,"price_display":"10.60","price_state":"stated","total_value":265869.2,"total_display":"265,869.20","total_whole":"265,869","shares_owned_after":4486390.0,"shares_owned_after_display":"4,486,390","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-27","filed_date":"2016-06-01","scope":"insider"},{"id":2267802,"accession":"0000899243-16-021120","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-021120","line_url":"/filing/0000899243-16-021120#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39887.0,"shares_display":"39,887","price_per_share":10.43,"price_display":"10.43","price_state":"stated","total_value":416021.41,"total_display":"416,021.41","total_whole":"416,021","shares_owned_after":4511472.0,"shares_owned_after_display":"4,511,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-26","filed_date":"2016-05-27","scope":"insider"},{"id":2267799,"accession":"0000899243-16-021120","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-021120","line_url":"/filing/0000899243-16-021120#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11456.0,"shares_display":"11,456","price_per_share":10.02,"price_display":"10.02","price_state":"stated","total_value":114789.12,"total_display":"114,789.12","total_whole":"114,789","shares_owned_after":4551359.0,"shares_owned_after_display":"4,551,359","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-25","filed_date":"2016-05-27","scope":"insider"},{"id":2640546,"accession":"0000899243-16-020907","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-020907","line_url":"/filing/0000899243-16-020907#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1200.0,"shares_display":"1,200","price_per_share":10.0,"price_display":"10.00","price_state":"stated","total_value":12000.0,"total_display":"12,000.00","total_whole":"12,000","shares_owned_after":4562815.0,"shares_owned_after_display":"4,562,815","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-24","filed_date":"2016-05-25","scope":"insider"},{"id":2640541,"accession":"0000899243-16-020907","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-020907","line_url":"/filing/0000899243-16-020907#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12053.0,"shares_display":"12,053","price_per_share":10.1,"price_display":"10.10","price_state":"stated","total_value":121735.3,"total_display":"121,735.30","total_whole":"121,735","shares_owned_after":4564015.0,"shares_owned_after_display":"4,564,015","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-23","filed_date":"2016-05-25","scope":"insider"},{"id":2160798,"accession":"0000899243-16-020709","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-16-020709","line_url":"/filing/0000899243-16-020709#line-2","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6187.0,"shares_display":"6,187","price_per_share":10.09,"price_display":"10.09","price_state":"stated","total_value":62426.83,"total_display":"62,426.83","total_whole":"62,427","shares_owned_after":4576068.0,"shares_owned_after_display":"4,576,068","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-20","filed_date":"2016-05-23","scope":"insider"},{"id":2160788,"accession":"0000899243-16-020709","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-020709","line_url":"/filing/0000899243-16-020709#line-1","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":null,"owner_name":"Canaan Partners IX LLC; Canaan IX L.P.","owner_display_name":"Canaan Partners IX LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":10.14,"price_display":"10.14","price_state":"stated","total_value":25350.0,"total_display":"25,350.00","total_whole":"25,350","shares_owned_after":4582255.0,"shares_owned_after_display":"4,582,255","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-19","filed_date":"2016-05-23","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Director, Ten percent owner","n_filings":15,"first_seen":"2016-05-23","last_seen":"2016-12-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001654586","retrieved_at":"2026-08-23T17:11:21+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}